Abstract: In one or more embodiments, one or more systems, method, and/or processes may receive processor instructions via an out-of-band system of an information handling system (IHS) and store the processor instructions via a storage device. For example, the processor instructions may be stored via a hidden partition of the storage device. While the out-of-band system receives the processor instructions, one or more of the IHS and a processor of the IHS may be in a low-power state. For example, the processor may not execute any instructions in the low-power state. While the out-of-band system receives the processor instructions, one or more of the IHS, an operating system of the IHS, and IHS firmware of the IHS may be impaired or inoperable, and the processor instructions may provide one or more remedies and/or repairs. In one or more embodiments, the IHS may be booted after the processor instructions are stored.

Abstract: Systems and methods for agentless remediation and recovery. In an illustrative, non-limiting embodiment, an Information Handling System (IHS) may include a Central Processing Unit (CPU); a Basic Input/Output System (BIOS) coupled to the CPU; a logic controller coupled to the CPU; and a memory coupled to the logic controller, the memory having program instructions stored thereon that, upon execution by the logic controller, cause the IHS to: during a first stage, check an operational state of a plurality of hardware components within the IHS in the absence of any involvement by the CPU or the BIOS; and during a second stage following the first stage, identify a failed hardware component amongst the plurality of hardware components in the absence of any involvement by the CPU or the BIOS.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

Abstract: An information handling system includes a primary integrated display device housing and a second integrated display device housing attached via a hinge and a processor to determine a first relative orientation of the primary integrated display device housing to the second integrated display device housing from a plurality of orientation sensors. The processor further determines a working software application context by detecting at least a first software application running on the information handling system wherein the working software application context further includes an operating state rank of the first software application relative to other software applications.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In Cparticular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated dis orders.

Abstract: Systems and methods for protected local backup. In an illustrative, non-limiting embodiment, an Information Handling System (IHS) may include one or more processors and a memory coupled to the one or more processors, the memory including program instructions stored thereon that, upon execution by the one or more processors, cause the IHS to: receive, via a file system filter driver, a request targeting a file system within a storage device, wherein the file system filter driver is owned by a backup application; and reject the request, via the file system filter driver, in response to the request having been issued by an application other than the backup application.

Abstract: Software services are managed from a single machine performing a service. Service providers offering SaaS applications solicit the single machine. Each service provider provides roles and device requirements for performing the corresponding SaaS. The single machine maintains a database that logs the software services offered by the service providers. Whenever a software service is needed, the single machine inventories its client devices for their resource capabilities and compares to the device requirements in the database. The database reveals the client machine(s) that best performs the role for the corresponding SaaS. Software services are thus integrated and managed from the single machine, thus allowing software services to be efficiently and quickly selected as network resources emerge.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: Various technologies described herein pertain to combining high dynamic range techniques to enable rendering higher dynamic range scenes with an image sensor. The image sensor can implement a combination of spatial exposure multiplexing and temporal exposure multiplexing, for example. By way of another example, the image sensor can implement a combination of spatial exposure multiplexing and dual gain operation. Pursuant to another example, the image sensor can implement a combination of temporal exposure multiplexing and dual gain operation. In accordance with yet another example, the image sensor can implement a combination of spatial exposure multiplexing, temporal exposure multiplexing, and dual gain operation. The image sensor can be formed on a single wafer or the image sensor can be a 3D-IC image sensor that includes at least two vertically integrated layers.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: A method and information handling system for obtaining information handling system wear parameter values representative of wear of the information handling system, the information handling system wear parameter sensors comprising a motherboard event wear parameter sensor for obtaining motherboard event wear parameter values, a component event wear parameter sensor for obtaining component event wear parameter values, and a usage wear parameter sensor for obtaining usage wear parameter values, for calculating client information handling system wear based on the information handling system wear parameter values and the statistical model of wear estimation, and for providing a service life indication for the client information handling system, the service life indication indicative of a disposition suitability.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: A method and information handling system comprising receiving, at the management information handling system, legacy client information handling system configuration parameter values of the legacy client information handling system, information handling system configuration parameter values comprising motherboard configuration parameter values and component configuration parameter values, storing the legacy client information handling system configuration parameter values in a memory device, and identifying, via a processor at the management information handling system, replacement client information handling system performance enhancements relative to legacy client information handling system performance constraints. Executing, via an application processor, instructions of a system configuration management system to determine replacement client information handling system configuration parameter values based on the replacement client information handling system performance enhancements.

Abstract: Various technologies described herein pertain to combining high dynamic range techniques to enable rendering higher dynamic range scenes with an image sensor. The image sensor can implement a combination of spatial exposure multiplexing and temporal exposure multiplexing, for example. By way of another example, the image sensor can implement a combination of spatial exposure multiplexing and dual gain operation. Pursuant to another example, the image sensor can implement a combination of temporal exposure multiplexing and dual gain operation. In accordance with yet another example, the image sensor can implement a combination of spatial exposure multiplexing, temporal exposure multiplexing, and dual gain operation.